دورية أكاديمية
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates.
| العنوان: | Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. |
|---|---|
| المؤلفون: | Tukhvatulin AI; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Gordeychuk IV; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Dolzhikova IV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Dzharullaeva AS; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Krasina ME; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Bayurova EO; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Grousova DM; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Kovyrshina AV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Kondrashova AS; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Avdoshina DV; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Gulyaev SA; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Gulyaeva TV; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Moroz AV; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Illarionova VV; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Zorkov ID; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Iliukhina AA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Shelkov AY; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Botikov AG; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Erokhova AS; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Shcheblyakov DV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Esmagambetov IB; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Zubkova OV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Tokarskaya EA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Savina DM; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Vereveyko YR; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Ungur AS; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Naroditsky BS; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Ishmukhametov AA; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Logunov DY; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Gintsburg AL; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia. |
| المصدر: | Emerging microbes & infections [Emerg Microbes Infect] 2022 Dec; Vol. 11 (1), pp. 2229-2247. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101594885 Publication Model: Print Cited Medium: Internet ISSN: 2222-1751 (Electronic) Linking ISSN: 22221751 NLM ISO Abbreviation: Emerg Microbes Infect Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2019- : [Philadelphia, PA] : Taylor & Francis Original Publication: New York : NPG, 2012-2018. |
| مواضيع طبية MeSH: | COVID-19*/prevention & control , COVID-19 Vaccines*, Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; Cytokines ; Humans ; Immunogenicity, Vaccine ; Immunoglobulin A ; Immunoglobulin G ; Leukocytes, Mononuclear ; Mice ; Pandemics/prevention & control ; Primates ; SARS-CoV-2/genetics |
| مستخلص: | Although unprecedented efforts aiming to stop the COVID-19 pandemic have been made over the past two years, SARSCoV-2 virus still continues to cause intolerable health and economical losses. Vaccines are considered the most effective way to prevent infectious diseases, which has been reaffirmed for COVID-19. However, in the context of the continuing virus spread because of insufficient vaccination coverage and emergence of new variants of concern, there is a high demand for vaccination strategy amendment. The ability to elicit protective immunity at the entry gates of infection provided by mucosal vaccination is key to block virus infection and transmission. Therefore, these mucosal vaccines are believed to be a "silver bullet" that could bring the pandemic to an end. Here, we demonstrate that the intranasally delivered Gam-COVID-Vac (Sputnik V) vaccine induced a robust (no less than 180 days) systemic and local immune response in mice. High immunogenic properties of the vaccine were verified in non-human primates (common marmosets) by marked IgG and neutralizing antibody (NtAb) production in blood serum, antigen-specific Tcell proliferation and cytokine release of peripheral blood mononuclear cells accompanied by formation of IgA antibodies in the nasal mucosa. We also demonstrate that Sputnik V vaccine can provide sterilizing immunity in K18-hACE2 transgenic mice exposed to experimental lethal SARS-CoV-2 infection protecting them against severe lung immunopathology and mortality. We believe that intranasal Sputnik V vaccine is a promising novel needle-free mucosal vaccine candidate for primary immunization as well as for revaccination and is worth further clinical investigation. |
| References: | Nat Med. 2021 Jul;27(7):1280-1289. (PMID: 34017137) Cell Rep Med. 2021 Nov 16;2(11):100448. (PMID: 34723223) J Med Virol. 2022 Jan;94(1):388-392. (PMID: 34415572) J Immunol. 2012 Sep 15;189(6):2702-6. (PMID: 22896631) Mil Med Res. 2021 Aug 31;8(1):47. (PMID: 34465396) Nat Commun. 2020 Aug 21;11(1):4198. (PMID: 32826914) Hum Vaccin Immunother. 2014;10(10):2875-84. (PMID: 25483662) Viruses. 2022 Jan 19;14(2):. (PMID: 35215783) Nat Rev Immunol. 2022 Apr;22(4):236-250. (PMID: 34312520) J Virol. 2010 Sep;84(18):9318-25. (PMID: 20610717) Hum Vaccin Immunother. 2022 Nov 30;18(5):2045853. (PMID: 35258416) Comput Struct Biotechnol J. 2021;19:976-988. (PMID: 33558827) Mucosal Immunol. 2022 Apr;15(4):584-594. (PMID: 35505121) Am J Primatol. 2020 Jun;82(6):e23128. (PMID: 32246726) mBio. 2022 Jan 11;:e0337921. (PMID: 35012339) Cytometry A. 2011 Feb;79(2):95-101. (PMID: 21265003) Nature. 2021 Feb;590(7847):630-634. (PMID: 33276369) Lancet. 2021 Feb 20;397(10275):671-681. (PMID: 33545094) Pathogens. 2022 Jan 19;11(2):. (PMID: 35215061) Toxicol Pathol. 2006;34(3):252-69. (PMID: 16698724) Lancet. 2020 Sep 26;396(10255):887-897. (PMID: 32896291) Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089) Lancet Reg Health Eur. 2021 Dec;11:100241. (PMID: 34746910) Nature. 2020 Jul;583(7818):830-833. (PMID: 32380511) Nat Protoc. 2007;2(9):2049-56. (PMID: 17853860) J Immunol. 2004 Aug 1;173(3):1978-86. (PMID: 15265932) Expert Opin Biol Ther. 2004 Jun;4(6):861-8. (PMID: 15174968) Environ Health Perspect. 1990 Apr;85:231-8. (PMID: 2116960) Nat Immunol. 2020 Nov;21(11):1327-1335. (PMID: 32839612) |
| فهرسة مساهمة: | Keywords: COVID-19; Gam-COVID-Vac; SARS-CoV-2; Sputnik V; intranasal vaccine |
| المشرفين على المادة: | 0 (Antibodies, Neutralizing) 0 (Antibodies, Viral) 0 (COVID-19 Vaccines) 0 (Cytokines) 0 (Immunoglobulin A) 0 (Immunoglobulin G) |
| تواريخ الأحداث: | Date Created: 20220829 Date Completed: 20220928 Latest Revision: 20220930 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9518644 |
| DOI: | 10.1080/22221751.2022.2119169 |
| PMID: | 36031930 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 2222-1751 |
|---|---|
| DOI: | 10.1080/22221751.2022.2119169 |